Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -17.48% is 224% below its 5-year average of 14.08%, near the high end of its 5-year range (-231.10%–63.45%).
43.44% below its 12-month average of -12.19%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-28): 15.04%.
EBITDA MARGIN
-17.48%
EBITDA MARGIN AVG TTM
-12.19%
EBITDA MARGIN AVG 3Y
10.49%
EBITDA MARGIN AVG 5Y
14.08%
EBITDA MARGIN AVG 10Y
19.04%
EBITDA MARGIN AVG 15Y
14.67%
EBITDA MARGIN AVG 20Y
15.76%
CURRENT VS TTM AVG
-43.44%
CURRENT VS 3Y AVG
-266.59%
CURRENT VS 5Y AVG
-224.12%
CURRENT VS 10Y AVG
-191.79%
CURRENT VS 15Y AVG
-219.12%
CURRENT VS 20Y AVG
-210.90%
QuidelOrtho Corporation
Market Cap
$857.16M
EBITDA Margin
-17.48%
TTM Avg
-12.19%
3Y Avg
10.49%
5Y Avg
14.08%
Market Cap
$855.38M
EBITDA Margin
-1761.78%
TTM Avg
-1761.78%
3Y Avg
-1761.78%
5Y Avg
-1761.78%
Market Cap
$853.13M
EBITDA Margin
43.46%
TTM Avg
29.10%
3Y Avg
-0.91%
5Y Avg
-6.21%
Market Cap
$852.35M
EBITDA Margin
-170.39%
TTM Avg
-102.27%
3Y Avg
-63.10%
5Y Avg
-63.10%
Market Cap
$867.03M
EBITDA Margin
-9.76%
TTM Avg
-14.11%
3Y Avg
-27.72%
5Y Avg
-36.15%
Market Cap
$870.81M
EBITDA Margin
-5250.17%
TTM Avg
-5250.17%
3Y Avg
-5250.17%
5Y Avg
-5250.17%
Market Cap
$838.62M
EBITDA Margin
-32.91%
TTM Avg
-153.12%
3Y Avg
-170.67%
5Y Avg
-159.26%
Market Cap
$838.16M
EBITDA Margin
-68.63%
TTM Avg
-68.17%
3Y Avg
-9114.49%
5Y Avg
-9114.49%
Market Cap
$833.81M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| QuidelOrtho Corporation (QDEL) | $857.16M | -17.48% | -12.19% | 10.49% | 14.08% |
| Alumis Inc. (ALMS)vs › | $855.38M | -1761.78% | -1761.78% | -1761.78% | -1761.78% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 43.46% | 29.10% | -0.91% | -6.21% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -170.39% | -102.27% | -63.10% | -63.10% |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | -9.76% | -14.11% | -27.72% | -36.15% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | -5250.17% | -5250.17% | -5250.17% | -5250.17% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -32.91% | -153.12% | -170.67% | -159.26% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -68.63% | -68.17% | -9114.49% | -9114.49% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | -37.08% | -66.80% | -66.80% | -66.80% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | -189.51% | -701.94% | -497.69% | -575.23% |
Gross Margin
44.6%
EBITDA Margin
-17.5%
Operating Margin
-30.7%
Net Margin
-39.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-28 | 15.04% |
| 2026-03-29 | 13.79% |
| 2025-12-28 | 6.38% |
| 2025-09-28 | -84.68% |
| 2025-06-29 | -11.47% |
| 2025-03-30 | 20.16% |
| 2024-12-29 | 1.26% |
| 2024-09-29 | 17.62% |
| 2024-06-30 | -0.22% |
| 2024-03-31 | -231.10% |
| 2023-12-31 | 20.94% |
| 2023-10-01 | 18.74% |
| 2023-07-02 | 13.17% |
| 2023-04-02 | 25.27% |
| 2022-12-31 | 23.44% |
| 2022-10-02 | 20.54% |
| 2022-07-03 | 20.74% |
| 2022-03-31 | 63.45% |
| 2021-12-31 | 61.41% |
| 2021-09-30 | 57.77% |
| 2021-06-30 | 19.93% |
| 2021-03-31 | 63.11% |
| 2020-12-31 | 77.78% |
| 2020-09-30 | 67.29% |
| 2020-06-30 | 47.34% |
| 2020-03-31 | 36.65% |
| 2019-12-31 | 32.93% |
| 2019-09-30 | 26.06% |
| 2019-06-30 | 16.91% |
| 2019-03-31 | 29.14% |
| 2018-12-31 | 29.78% |
| 2018-09-30 | 23.51% |
| 2018-06-30 | 11.58% |
| 2018-03-31 | 37.35% |
| 2017-12-31 | 14.65% |
| 2017-09-30 | -0.07% |
| 2017-06-30 | -22.57% |
| 2017-03-31 | 29.20% |
| 2016-12-31 | 21.05% |
| 2016-09-30 | 8.91% |
| 2016-06-30 | -17.20% |
| 2016-03-31 | -2.47% |
| 2015-12-31 | 9.31% |
| 2015-09-30 | 7.33% |
| 2015-06-30 | -21.81% |
| 2015-03-31 | 17.76% |
| 2014-12-31 | 23.77% |
| 2014-09-30 | -19.37% |
| 2014-06-30 | -24.70% |
| 2014-03-31 | 0.04% |
| 2013-12-31 | 4.55% |
| 2013-09-30 | -11.32% |
| 2013-06-30 | -17.17% |
| 2013-03-31 | 30.57% |
| 2012-12-31 | 29.46% |
| 2012-09-30 | 1.53% |
| 2012-06-30 | -9.07% |
| 2012-03-31 | 5.76% |
| 2011-12-31 | 20.54% |
| 2011-09-30 | 1.65% |
| 2011-06-30 | -6.24% |
| 2011-03-31 | 33.10% |
| 2010-12-31 | 9.31% |
| 2010-09-30 | -4.96% |
| 2010-06-30 | -22.93% |
| 2010-03-31 | -5.66% |
| 2009-12-31 | 50.55% |
| 2009-09-30 | 43.81% |
| 2009-06-30 | 9.89% |
| 2009-03-31 | -18.08% |
| 2008-12-31 | 33.65% |
| 2008-09-30 | 29.55% |
| 2008-06-30 | 4.50% |
| 2008-03-31 | 38.24% |
| 2007-12-31 | 35.63% |
| 2007-09-30 | 22.38% |
| 2007-06-30 | -3.90% |
| 2007-03-31 | 30.53% |
| 2006-12-31 | 35.65% |
| 2006-09-30 | 16.54% |
| 2006-06-30 | -12.13% |
| 2006-03-31 | 26.60% |
| 2005-12-31 | 30.46% |
| 2005-09-30 | 8.20% |
| 2005-06-30 | -11.60% |
| 2005-03-31 | -63.22% |
| 2004-12-31 | 33.17% |
| 2004-09-30 | -32.15% |
| 2004-06-30 | -24.21% |
| 2004-03-31 | 6.36% |
| 2003-12-31 | 29.40% |
| 2003-09-30 | -1.00% |
| 2003-06-30 | 0.23% |
| 2003-03-31 | 14.32% |
| 2002-12-31 | 9.93% |
| 2002-09-30 | -9.43% |
